We are committed to finding a cure for WM.

Ibrutinib Monotherapy Clinical Trial Data

For those who are interested in learning about the current activity with Ibrutinib, please read the article below. This is the PR news release on the presentation in Lugano on Ibrutinib activity in relapsed/refractory WM which Dr. Treon had done a few weeks ago in Lugano, Switzerland during the Lymphoma Conference.  Well over 3,000 physicians attended his lecture on this drug.


Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstrom’s Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland (via PR Newswire)

SUNNYVALE, Calif., June 20, 2013 /PRNewswire/ — Pharmacyclics, Inc. (the “Company”) (Nasdaq: PCYC) today announced results of a study evaluating ibrutinib, an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor in patients with Waldenstrom…